(1,3)-Béta-D-Glucan Levels at Diagnosis of Juvenile Idiopathic Arthritis and Its Correlation With Activity's Disease : a Cohort Sudy (BDG -JIA)

Centre Hospitalier Universitaire, Amiens

Status: Completed

Conditions: Juvenile Idiopathic Arthritis

Treatments: Biological: (1-3)-ß-D-Glucan (BDG) assay (Fungitell); Diagnostic Test: The Juvenile Disease Activity Score (JADAS)

Study type: Interventional

Funder types: Other

Identifiers

NCT03984669

PI2018_843_0036

Details and patient eligibility

About

Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease of childhood. Most children still experience prolonged periods of active disease, however, there is still lack of effective and specific markers for early diagnosis of relapse. The pathogenesis of JIA is thought to be the result of a combination of host genetic and environmental triggers and The microbiota is a potential contributing factor to the development of the disease. (1-3)-ß-D-Glucan (BDG), a component of most fungal cell walls, possess immunomodulatory activities. Latest studies demonstrate that it acts as a trigger for autoimmune arthritis in adult. However the relation with JIA is not clearly defined. The objective of this study was to evaluate the (1,3)-Béta-D-Glucans level in patients with JIA and whether higher serum BDG levels are correlated with JIA activity of disease, comparatively with usual markers.

Enrollment: 40 patients

Sex: All

Ages: Under 18 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• All patients under the age of 18 years with JIA's disease
• followed at the CHU Amiens (French University hospital)
• signed parent consent form

Exclusion criteria

• lack of consent from parents or patient

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)